[Reuters - UK Focus] – Pfizer Inc on Monday said one of its experimental drugs had failed to meet its goals in two late-stage studies among patients who had received prior treatment for advanced non-small cell lung cancer, the …
Read more on … [visit site to read more]
- Amgen Inc. (NASDAQ:AMGN) – Amgen cholesterol drug succeeds in late-stage trial
- Company Update: Amgen Inc. (NASDAQ:AMGN) – Ahead of the Bell: Amgen’s cholesterol drug
- Company Update: Johnson & Johnson (NYSE:JNJ) – AstraZeneca to co-promote J&J prostate cancer drug in Japan